Affiliations 

  • 1 Discipline of Clinical Pharmacy, School of Pharmaceutical Science, Universiti Sains Malaysia, Penang, Malaysia
  • 2 Pharmacy Department, Dubai Health Authority, Dubai, United Arab Emirates
PLoS One, 2014;9(4):e95991.
PMID: 24755778 DOI: 10.1371/journal.pone.0095991

Abstract

Adverse drug reactions (ADRs) represent a major burden on the healthcare system. Chronic kidney disease (CKD) patients are particularly vulnerable to ADRs because they are usually on multiple drug regimens, have multiple comorbidities, and because of alteration in their pharmacokinetics and pharmacodynamic parameters. Therefore, one step towards reducing this burden is to identify patients who are at increased risk of an ADR.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.